Abstract
The widely used antidepressants Specific Serotonin Reuptake Inhibitors (SSRI) have been tried with success as anticonvulsants in cases of nonsymptomatic epilepsy. This attempt was performed on the basis of experimental data suggesting the involvement of impairments of the serotonin system in the genesis of epilepsy. This overview summarizes the clinical data and presents biochemical and neurochemical evidences suggesting the mechanism of the therapeutic effects of SSRI in nonsymptomatic epilepsy. In particular, studies on blood-borne neutral amino acids and platelet serotonin transporter (SERT) in epileptics suggest: (a) That a decreased brain availability of tryptophan may be related to some types of epilepsy. (b) That reduction of the density of SERT may be a homeostatic reaction in the brain following epileptic seizures.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Scudder CL, Karczmar AG, Everett GM, Gibson JE, Rifkin M (1966) Brain catecholamines and serotonin values in various strains and genera of mice and a possible interpretation for the correlation of amine with electroshock latency and behaviour. Int J Neuropharmacol 5:343–351
Yan QS, Jobe PC, Dailey JW (1993) Evidence that a serotonergic mechanism is involved in the anticonvulsant effect of fluoxetine in genetically epilepsy-prone rats. Eur J Pharmacol 252:105–112
Jobe PC, Browning RA (2005) The serotonergic and noradrenergic effects of antidepressant drugs are anticonvulsant, not proconvulsant. Epilepsy Behav 7:602–619
Delay J, Deniker P, Lemperiere T, Ropert M, Colin W, Ogrizek B (1959) Study of the effectiveness of imipramine in the treatment of depressive states. Ann Med Psychol 117:521–531
Trimble M (1978) Non-monoamine oxidase inhibitor antidepressants and epilepsy: a review. Epilepsia 19:241–250
Barbey JT, Rose SP (1998) SSRI safety in overdose. J Clin Psychiatry 59(Suppl. 15):42–48
Leander JD (1992) Fluoxetine, a selective serotonin-uptake inhibitor, enhances the anticonvulsant effects of phenytoin, carbamazepine, and ameltolide. Epilepsia 33:573–576
Pasini A, Tortorella A, Gale K (1992) Anticonvulsant action of intranigral fluoxetine. Brain Res 593:287–290
Prendiville S, Gale K (1993) Anticonvulsant effect of fluoxetine on focally evoked limbic motor seizures in rats. Epilepsia 34:381–384
Wada Y, Shiraishi J, Nakamura M, Hasegawa H (1995) Prolonged but not acute fluoxetine administration produces its inhibitory effect on hippocampal seizures in rats. Psychopharmacology 118:305–309
Boggan WO, Seiden LS (1973) 5-Hydroxytryptophan reversal of reserpine enhancement of audiogenic seizure susceptibility in mice. Physiol Behav 10:9–12
Truscott TC (1975) Effect of phenylalanine and 5-hydroxytryptophan on seizure severity in mice. Pharmacol Biochem Behav 3:939–941
Favale E, Rubino V, Mainardi P, Lunardi G, Albano C (1995) Anticonvulsant effect of fluoxetine in humans. Neurology 45:1926–1927
Favale E, Audenino D, Cocito L, Albano C (2003) The anticonvulsant effect of citalopram as an indirect evidence of serotoninergic impairment in human epileptogenesis. Seizure 12:316–318
Baldessarini RJ (1996) Drugs and the treatment of psychiatric disorders: depression and mania. In: Hardman JG, Goodman Gilman A, Limbird LE (eds) Goodman & Gilman’s the pharmacological basis of therapeutics, 9th edn. McGraw-Hill, New York, pp 431–459
Lunardi G, Mainardi P, Rubino V, Fracassi M, Pioli F, Cultrera S, Albano C (1996) Tryptophan and epilepsy. In: Allegri Filippini G, Costa CVL, Bertazzo A (eds) Recent advances in tryptophan research. Plenum Press, New York, pp 101–102
Frazer A, Hensler JG (1999) Serotonin. In: Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD (eds) Basic neurochemistry, 6th edn. Lippincott Williams & Wilkins, Philadelphia, pp 263–292
Smith QR, Momma S, Aoyagi M, Rapoport SI (1987) Kinetics of neutral amino acid transport across the blood-brain barrier. J Neurochem 49:1651–1658
Cupello A, Favale E, Audenino D, Scarrone S, Gastaldi S, Albano C (2005) Decrease of serotonin transporters in blood platelets after epileptic seizures. Neurochem Res 30:1–4
Lesch KP, Wolozin BL, Murphy DL, Reiderer P (1993) Primary structure of human platelet serotonin uptake site: identity with the brain serotonin transporter. J Neurochem 60:2319–2322
Cappelli A, Giuliani G, Gallelli A, Valenti S, Anzini M, Mennuni L, Makovec F, Cupello A, Vomero S (2005) Structure-affinity relationship studies on arylpiperazine derivatives related to quipazine as serotonin transporter ligands. Molecular basis of the selectivity SERT/5HT3 receptor. Bioorg Med Chem 13:3455–3460
Paul SM, Rehavi M, Skolnick P, Ballenger JC, Goodwin FK (1981) Depressed patients have decreased binding of tritiated imipramine to platelet serotonin “transporter”. Arch Gen Psychiatry 38:1315–1317
Da Prada M, Cesura AM, Launay JM, Richards JG (1988) Platelet as a model for neurons? Experientia 44:115–126
Newport DJ, Owens MJ, Knight DL, Ragan K, Morgan N, Nemeroff CB, Stowe ZN (2004) Alterations in platelet serotonin transporter binding in women with postpartum onset major depression. J Psychiatry Res 38:467–473
Atkins PW (1986) Physical chemistry, 3rd edn. Oxford University Press, Oxford
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Albano, C., Cupello, A., Mainardi, P. et al. Successful Treatment of Epilepsy with Serotonin Reuptake Inhibitors: Proposed Mechanism. Neurochem Res 31, 509–514 (2006). https://doi.org/10.1007/s11064-006-9045-7
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11064-006-9045-7